Sleep disorders—including excessive daytime sleepiness (EDS) and obstructive sleep apnea (OSA)—are highly prevalent, yet primary care clinicians often don’t ask their patients about them. But the burden of sleep disorders is great: OSA, for example, has been associated with an increased risk for many adverse health outcomes, including increased all-cause and cardiovascular mortality, accidents, impaired productivity, and depression. This activity provides an overview of the evaluation and management of EDS in OSA. It reviews risk factors, screening and diagnostic tools, and appropriate use of nonpharmacologic and pharmacologic therapies.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able
- Recognize signs, symptoms, and risk factors for OSA and EDS in OSA
- Devise appropriate nonpharmacologic and pharmacologic treatment strategies for OSA and for EDS in OSA
- Integrate patient-centered, multidisciplinary strategies into the management of OSA and EDS in OSA
NPs and PAs
CNE Credit Designation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 0.50 hours of pharmacology credit
Nurse Planner: Susan M. Tiso, DNP, APRN, FNP-BC
PA Planner: Larry Herman, MPA, PA-C
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until March 26, 2020. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Doghramji: consultant: Eisai, Harmony Bioscience, Pfizer, Teva; consultant/grant/research support: Inspire Medical, Jazz, Merck.
None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the activity in its entirety
- Relate the content to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: March 26, 2019
Expiration date: March 26, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. JZPCE95818